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Abstract 
Embryonic stem (ES) cells provide an unlimited source of cells potentially useful for 
regenerative medicine, however, prior to clinical implementation, additional basic 
research is needed. This thesis is focused upon different molecular aspects regarding 
ES cells, primarily by finding novel stem cell protein-protein interactions and their 
functions.  
As functions of a specific protein may be dependent on its interacting partner, 
identification of such protein-protein interactions is important. Using several 
different methods, for example in situ proximity ligation assay and co-
immunoprecipitation, numerous novel protein-protein interactions occurring in ES 
cells were found. The same proteins were shown to be involved in several different 
protein complexes, some of them likely to be part of bigger complexes. Tpt1 and 
Npm1 were two such proteins found in several different interactions. Tpt1/Npm1 
interacted with a prominent peak during mitosis and were proven to be involved in 
cell proliferation. Individual depletion of Tpt1 and Npm1 resulted in increased levels 
of markers of the neural and mesodermal lineages, respectively. Further, Npm1 also 
associated with all three core transcription factors, namely Oct4, Sox2 and Nanog, 
signifying the importance of Npm1 in ES cells. The Npm1/Sox2 interaction was 
shown to remain while cells were induced to differentiate into neural lineage, while 
decreasing in the other differentiation pathways, indicating of an additional role of 
this protein complex during differentiation to ectoderm. Phosphorylated Ncl was 
found to interact individually with Tpt1 and Oct4 in a cell cycle dependent manner, 
speculatively involved in cell proliferation and transcription.  
In screening for factors binding to Oct4 proximal promoter, SAF-A was found and 
subsequently shown to be involved in the transcriptional regulation of Oct4. The 
binding occurred preferentially to unmethylated Oct4 promoter and was reduced 
when ES cells were induced to differentiate. SAF-A was also found to interact with 
RNA pol II as well as STAT3, Oct4 and Sox2.  
In conclusion: twelve novel protein-protein interactions, involved in cell 
proliferation, differentiation and transcriptional regulation, are presented in this 
thesis. 
Key words: embryonic stem cells, Tpt1, Npm1, Ncl, Oct4, Sox2, Nanog, SAF-A, 
cell proliferation, transcriptional regulation  
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Abbreviations 
BrdU 5-bromo-2-deoxyuridine 
Cdk cyclin dependent kinases 
ChIP chromatin immunoprecipitation 
DAPI 4,6-diamidino-2-phenylidole 
DMSO dimethyl sulfoxide 
EdU 5-ethynyl-2’-deoxyuridine 
ES embryonic stem 
GFP green fluorescent protein 
HMG high mobility group 
hnRNP heterogeneous nuclear ribonucleoprotein 
ICM inner cell mass 
IP immunoprecipitation 
iPS induced pluripotent stem 
JAK/STAT Janus kinase-signal transducer and activator 
LIF leukemia inhibitory factor 
Ncl nucleolin 
Ncl-P phosphorylated nucleolin 
Npm1 nucleophosmin 
Npm1-P phosphorylated nucleophosmin 
PLA proximity ligation assay 
Plk1 polo-like kinase 1 
POU pit-oct-unc 
qPCR quantitative real-time polymerase chain reaction 
RA retinoic acid 
Rb retinoblastoma 
SAF-A scaffold attachment factor A 
SCNT somatic cell nuclear transfer 
shRNA short hairpin ribonucleic acid 
SRR sox regulatory region 
SRY sex determining region Y 
SSEA stage-specific embryonic antigen 
Tpt1 translationally controlled tumor protein 
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Introduction 
A typical specialized somatic cell has its destiny set to a specific and generally 
irreversible cell fate. An important question in medicine and cancer biology is 
whether and how these cells could be programmed to adopt a different cellular fate. 
The answer would provide knowledge about how cell specialization is reset or 
maintained, which is of great interest in understanding cancer, and might open the 
way to personalized cell- and tissue-based treatments for Diabetes Mellitus and 
degenerative diseases like Alzheimer’s and Parkinson’s. The first step in this process 
is to reprogram cells toward a stem cell like state. The first experiment demonstrating 
that a vertebrate somatic cell nucleus could be reprogrammed back into an embryonic 
state was performed in 1962, when a nucleus was transferred from a differentiated 
intestinal epithelial cell into a Xenopus laevis egg, and generated a cloned embryo 
that developed into an adult frog
1
. This experimental approach was successfully 
repeated in mammals with Dolly the sheep in 1997
2
.   
It is equally important to understand how pluripotent stem cells can be developed 
into desired cell types. Embryonic stem (ES) cells are the perfect model for such 
experiments due to their capacity of unlimited self-renewal and pluripotency, i.e. 
having the possibility to give rise to all three embryonic germ layers: ectoderm, 
mesoderm and endoderm, as well as primordial germ cells. Identification of novel 
signaling pathways and transcriptional regulatory circuitry, and their role in self-
renewal capacity and pluripotency are essential for understanding early development 
as well as discovering the therapeutic potential of ES cells. In this thesis, we have 
identified important stem cell factors by finding novel protein-protein interactions 
and their functions. Depending on interaction partners, most proteins can be involved 
in several different cellular mechanisms, and it is therefore important to find and 
characterize these interactions to explore more aspects regarding pluripotency.   
 
Embryonic stem cells 
ES cells offer a unique opportunity to study early development and hold great 
promise for regenerative medicine, drug development and delivering gene therapies. 
ES cells are derived from the inner cell mass (ICM) of developing blastocysts of pre-
implantation embryos, and can be propagated indefinitely in culture in an 
undifferentiated state while maintaining the capacity to produce any cell type in the 
body, i.e. they are pluripotent (Figure 1). The first generated ES cell line originated 
from a mouse
3-4
 and it took almost 20 years before human ES cell lines were derived 
from donated in vitro fertilization leftover embryos
5
. Ethical issues about terminating 
embryos for creating ES cells lines is a major concern, which led to the development 
of a technique to create murine ES cell lines from single-cell embryo biopsy
6
, similar 
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to the method used for genetic defects screening
7
. The same technique has also been 
proven successful to create human ES cells without embryo destruction
8
. 
Furthermore, single-cell embryo biopsy provides an important route to obtain ES cell 
lines with specific genetic defects, which can be used for drug screening and 
potentially in the future also for genetic therapies.  
The generation of murine ES cells led to an enormous breakthrough in determining 
gene functions, with site-directed mutagenesis by gene targeting in ES cells, that 
could be reintroduced back into an embryo, giving the opportunity to create null 
mutants, hypomorphic mutants, introduce reporter genes to follow gene expression, 
as well as the possibility to study deletion of a gene in a specific organ or at a 
specific period during development
9
. Equally important was the fact that one could 
also do site-directed corrections in ES cells with specific mutations
10
. Some 
indications of what ES cells might be able to do for us in the future arise from 
different mouse disease models. For example, by transplanting ES cell derived 
dopaminergic neurons into a Parkinson’s disease mouse model, the disease 
phenotype was corrected
11
. One must bear in mind that ES cells need to be efficiently 
differentiated into the desired cell type and undifferentiated ES cells need to be 
eliminated from the differentiated cells, to reduce the risk of tumor development. It is 
therefore important to find distinctions between pluripotent and differentiated cell 
states. 
 
 
Figure 1. Derivation of ES cells from 
blastocysts and their pluripotent capacity. 
After fertilization the egg cell begins to divide, 
first synchronized i.e. all cells are similar, 
creating a morula. Then two different cell 
types emerge giving rise to the blastocyst, 
namely trophectoderm and ICM. In vitro 
culture of ICM results in undifferentiated ES 
cells. Such cells have unlimited self-renewal 
capacity and ability to differentiate toward all 
three embryonic germ layers. 
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ES cell characteristics 
ES cells have three distinct hallmarks, 1: unlimited self-renewal by symmetrical cell-
division, 2: capacity to differentiate into all cell types in the body, and 3: ability to 
contribute to functional tissue generation when incorporated back into embryos. 
Beside the above, ES cells have several additional characteristics: high nucleo-
cytoplasmic ratios, large nucleoli, rapid cell proliferation, positive staining for 
alkaline phosphatase, high telomerase activity, expression of specific pluripotency 
markers such as Oct4, Nanog, Sox2, Rex1, SSEA1 (murine), SSEA3 (human), 
SSEA4 (human), TRA-1-60 (human), TRA-1-81 (human)
12
.  
ES cells are tumorigenic when injected into severe combined immunodeficient mice, 
a property that is lost when ES cells have started to differentiate. In culture, murine 
ES cells form tight, rounded and multi-layer colonies, while human ES cells form flat 
and loose colonies
12
. As mentioned previously, the unlimited self-renewal occurs via 
symmetrical cell-division (Figure 2). That is a cell-division producing two new 
identical pluripotent ES cells without any differentiation. Adult stem cells often use 
asymmetrical cell-division to give rise to both a new stem cell as well as a 
differentiated cell. It is not known if ES cells ever divide asymmetrically or not.  
 
Signal transduction pathways 
Signal transduction pathways, sustained through addition of external factors, are 
required to keep ES cells in an undifferentiated state. First successful generation of 
murine ES cell lines required a feeder layer of mitotically inactivated fibroblast in 
combination with medium supplemented with fetal calf serum
3-4
. The feeder cells 
were later shown to be substitutable with the cytokine LIF
13-14
, while serum could be 
replaced with bone morphogenetic protein 4
15
. LIF has been shown to work through 
the JAK/STAT pathway, where activation of STAT3 plays a central role in the 
maintenance of pluripotency
16
. Wnt signaling, through the canonical pathway, has 
Figure 2. To maintain an 
undifferentiated state, ES cells 
divide symmetrically, giving rise 
to two new identical ES cells. 
Asymmetrical cell-division, 
which is common with adult 
stem cells, might also occur in 
ES cells, which would result in 
one ES cell and one desired  
differentiated cell. 
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been shown to enhance the effect of LIF to maintain pluripotent ES cells
17
. 
Additionally, the transcription factors Klf4 and Tbx3 were recently shown to be 
involved in connecting a parallel circuit of LIF signaling to the core transcription 
factors
18
. Murine and human ES cells are shown to respond to different signal 
transduction pathways. Unlike murine ES cells, human ES cells are maintaining 
pluripotency without involvement of LIF
19
 and instead need supplements of basic 
fibroblast growth factor 4 and activin as well as suppression of bone morphogenetic 
protein signaling, to stay in an undifferentiated state
20
. Recently it was reported that 
the external factors required for ES cell maintenance are used in signal transduction 
pathways to inhibit differentiation routes rather than for keeping the pluripotent 
state
21
.  
Human versus murine ES cells 
Differences between murine and human ES cells, like specific markers and signal 
transduction pathways, might be attributed to cell origins from different 
developmental stages. Murine epiblast stem cells derived from late epiblast layers of 
pre-gastrulation stage embryos share many characteristics with human ES cells, like 
growth requirements of added fibroblast growth factor and activin instead of LIF, and 
the ability to express trophoblast markers in vitro
22-23
. These similarities could be due 
to the fact that human ES cell isolation protocols use fibroblast growth factor and 
activin, which might select against “true” ES cells and instead result in epiblast stem 
cells. Murine ES cells may therefore origin from an earlier embryonic stage (ICM) 
compared to human ES cells (late epiblast), even though both types of ES cells are 
obtained from the blastocyst stage
24
. 
 
Similarities between ES and cancer cells 
Cancer cells share many properties with ES cells including the phenotype with large 
nucleoli and self-renewal in an immortalized fashion. Signaling pathways that 
promote ES cell self-renewal might very well exist also in cancer cells. All the 
similarities have led to the definition of the term cancer stem cells, with the 
hypothesis that cancer cells emerge from adult stem cells that become immortalized 
and taken back towards an ES cell like state. ES cell specific proteins, like Oct4, 
have been reported to be expressed in certain human tumors
25
, and embryonic gene 
expression patterns were shown to become reactivated in malignant tumors
26
, 
additionally strengthening the theory that cancer cells have a stem cell origin. 
Further, Oct4 is often found in testicular germ cell tumors and was proposed to be a 
dose-dependent oncogene, since high Oct4 levels were coupled with increased 
malignacy
27
.  
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Core transcription factors 
Three different core transcription factors have been proven essential for ES cell 
maintenance, namely Oct4, Sox2 and Nanog. They co-occupy a substantial portion of 
their target genes and form together a gene expression program consisting of both 
induction as well as repression of genes necessary for self-renewal, pluripotency or 
differentiation
28-29
. Besides their strict regulation pattern with feedforward loops they 
also perform autoregulatory loops on their own expression (Figure 3).  In the 
subsequent sections, these three core transcription factors will be presented one by 
one. 
 
Oct4 
Oct4 (also known as Pou5f1, Oct-3, Oct3/4, Otf3 or NF-A3) belongs to the pit-oct-
unc (POU) transcription factor family. POU transcription factors were originally 
identified as DNA-binding proteins that are able to activate the transcription of genes 
containing an octameric sequence, called the octameric motif 5’-AGTCAAAT-3’, 
within the regulatory regions
30
. Oct4 is the first transcription factor to be expressed 
during mammalian embryonic development. Oct4 is detected already in oocytes, 
stays activated during morula stage, gets restricted and peaks in ICM at blastocyst 
stage, and from E5.5 only being present at low levels in primitive ectoderm, to totally 
disappear from E9, with the exception of primordial germ cells
31
. These observations 
were confirmed at the protein level
32
. However, instead of decreased Oct4 levels at 
E5.5, higher Oct4 levels were observed compared to ICM, as well as that maternally 
expressed Oct4 was degraded before the end of the two-cell stage
32
.  
Knockout mice deficient in both Oct4 alleles result in peri-implantation embryonic 
lethality and even though blastocyst embryos appear to be normal, they lack the 
pluripotent ICM and instead only develop into trophoblast cells when outgrown
33
. 
Oct4 is therefore considered to be essential for generating the pluripotent cell 
population in mammalian embryos, where it is involved in the maintenance of an 
undifferentiated, pluripotent ES cell state. Surprisingly, Oct4 expression is not 
Figure 3. Autoregulation of the three core 
transcription factors. All three core 
transcription factors are involved both in 
their own as well as the others regulation of 
expression. Oct4/Sox2 bind and regulate all 
three proteins as a complex, while Nanog 
binds and regulates all three proteins by 
itself. 
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sufficient to maintain undifferentiated ES cells in the absence of LIF
34
. On the other 
hand, a precise level of Oct4 is essential to maintain ES cell pluripotency, given that 
a twofold increase or decrease in Oct4 triggers differentiation towards 
endoderm/mesoderm or trophectoderm, respectively
34
.  
Although Oct4’s endogenous expression normally is thought to be tightly restricted 
to ES cells, germ cells and embryonic carcinoma cells
31,33
, Oct4 expression has also 
been reported in various types of cancer cells
25
. When ectopically expressing Oct4 in 
adult mice somatic tissues it results in dysplastic growths, which are dependent on 
continuous Oct4 expression
35
. Otherwise the tumor growths are fully reversible. 
Immature cells were required for Oct4 to be able to function similarly as it does in 
ES cells, that is maintaining a stem cell state and preventing differentiation
35
. Oct4 
has also been reported to be important for successful nuclear reprogramming, where 
distribution and level of Oct4 showed consequences for pluripotency and 
development of somatic cell clones
36
. A few years ago, a new method to reprogram 
somatic cells using retroviral transduction of specific transcription factors further 
proved that Oct4 is one of the necessary components to succeed with reprogramming 
cells to a pluripotent state
37-40
.  
 
Sox2 
Sox2 belongs to the SRY-related HMG-box family of genes, which are expressed 
during different embryonic developmental phases, with the HMG domain binding to 
a specific DNA motif 5’-(A/T)(A/T)CAA(A/T)G-3’41-42. The Sox family of proteins 
are divided into several groups and subgroups, where Sox2 belongs to B1, together 
with Sox1 and Sox3
43
. HMG proteins bind DNA in a unique way at the minor groove 
of the DNA-helix, resulting in an induction of a strong DNA bend
42
. This property 
has led to the hypothesis that Sox proteins function partly by organizing local 
chromatin structures, enabling other transcription factors bound at adjacent DNA 
sites into biologically active complexes, or facilitating the interaction between distant 
enhancer nucleoprotein complexes with the basal transcription sites
41-42
. To perform 
this function, the Sox proteins seem to require interactions with different partners and 
only then can they form a stable complex with the target DNA
43
. The different Sox-
interaction partner complexes are likely to be involved in the regulated fashion of 
Sox proteins being expressed and active during most of the embryonic developmental 
phases
41-43
. 
During embryonic development Sox2 is first detected at morula stage, followed by 
specific expression in ICM during blastocyst stage, and from E7.5 the expression is 
further restricted to neuroectodermal progenitor cells and primordial germ cells
44
. 
Knockout mice depleted of both Sox2 alleles are embryonic lethal and die shortly 
after implantation, although appearing normal at blastocyst stage
44
. However, without 
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Sox2 the epiblast does not form and only trophoblast giant cells survive from what 
normally would be ICM
44
. In accordance with this, it has been shown that Sox2 
depleted ES cells differentiate to mature trophoblast cells, but this could be inhibited 
by overexpressing Oct4
45
.  
Somewhat contradictory reports about Sox2 overexpression exist, one claiming that 
overexpression of Sox2 does not affect self-renewal or the undifferentiated state of 
ES cells, nor affect their differentiation capacity when induced to differentiate by LIF 
deprivation
46
. However, withdrawal of both serum and LIF suppressed mesodermal 
and endodermal lineage formation, and only neural phenotypes were developed
46
. 
Contradictory, it has been shown that just a small increase in Sox2 levels induced ES 
cells to differentiate toward several different cell types even in presence of LIF
47
. 
This is supported by that elevation of Sox2 levels inhibited endogenous expression of 
several Sox2:Oct4 target genes, including all three core transcription factors
48
.  
 
Nanog 
Nanog is the latest addition of the three core transcription factors, found by two 
independent groups in 2003
49-50
. It is named after “Tir nan Og”, which comes from 
the Celtic mythology, with the meaning: land of the ever young
49
. Nanog is a 
homeobox domain containing protein with a serine rich motif in the N-terminal and a 
tryptophan at every fifth position in the C-terminal
49
. These pentapeptide repeats 
constitute a potent transactivation subdomain, that together with another subdomain 
in the C-terminal are essential for Nanog to act as a transcription activator
51
. Nanog 
shows low homology with other homeobox domain protein families, with the NK2 
family of homeoproteins as its closest relative
49
.  
During embryonic development, Nanog expression is first detected in the interior 
cells of the morula, get maximal levels of expression between late morula and mid 
blastocyst stage, where Nanog first is located to ICM and absent from trophectoderm, 
to get further restricted into epiblast cells, and disappears at implantation
49
. Knockout 
mice deficient in both Nanog alleles are embryonic lethal and fail to develop beyond 
blastocyst stage since they cannot develop the epiblast
50
. At E3.5 they are 
indistinguishable from normal embryos but ES cells derived from Nanog null 
blastocysts do not stay as undifferentiated cells, instead completely differentiate into 
endoderm-like cells
50
. In accordance with this, it has been shown that RNAi 
depletion of Nanog in human
52
 and murine
53
 ES cells result in induction of 
extraembryonic endodermal lineages. However, another study found that depletion of 
Nanog in ES cells did not affect the undifferentiated cell state upon continous 
passaging, although slower proliferation and flatter morphology were observed
54
. 
The reduced proliferation could be explained with that Nanog has been implicated in 
G1 to S transition, where Nanog overexpression results in quicker cell cycle 
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progression through accelerated S-phase entry by direct binding and regulation of 
two proteins important for this process
55
. 
Nanog is to some extent very different from the other two core transcription factors. 
Heterogeneous expression of Nanog is observed in ES cells, where Nanog-high 
populations only express pluripotency markers, whereas Nanog-low populations also 
express markers for primitive endoderm
56
. It has also been shown that overexpression 
of Nanog is enough to maintain murine and human ES cells undifferentiated in 
absense of LIF
49-50
 or feeder layer
57
, respectively. The central role for Nanog in the 
transcription factor hierarchy for maintaining ES cell identity is further confirmed 
with its involvement in different nuclear reprogramming aspects
38,58
, discussed later. 
 
Transcriptional regulation 
Most cells in the human body have identical genomes, and the thing making a heart 
cell differ from a skin cell mostly depends on which genes they express. Different 
genes are active at different stages during development and an adult specialized 
somatic cell only expresses a minority of genes from the genome. The reason for this 
divergent expression in different cell types depend on for example: DNA 
methylations
59
, chromatin modifications
60
, and transcription factors either activating 
or repressing transcription. Gene transcription is regulated at so called cis-regulatory 
regions situated upstream of the transcription start site. These regions contain 
different binding sites where transcription factors can bind if they are accessible and 
unmethylated. Aspects about the transcriptional regulation of the three core 
transcription factors, with focus on Oct4, are summarized below. 
Oct4 
Regulation of Oct4 expression has been proven dependent on three upstream cis-
regulatory regions: the TATA-less proximal promoter, the proximal enhancer and the 
distal enhancer
61-62
. The two enhancer regions have been shown to control Oct4 
expression in different types of murine cells, with the distal enhancer active in ICM, 
ES cells and primordial germ cells, while the proximal enhancer functions in epiblast 
and embryonic carcinoma cells
62
. Four conserved regions of homology (termed CR1-
CR4) can be found within these three regulatory regions
61
. CR1 is positioned in the 
proximal promoter and consists of a putative Sp1/Sp3 site, a retinoic acid-responsive 
element (RARE), a steroidogenic factor-1 (SF-1) binding site and a 1A-like site
61,63-
65
. CR4 is located in the distal enhancer and contains an Octamer/Sox cis-regulatory 
element, proven to be required for Oct4 expression, where Sox2 and Oct4 together 
regulate the transcription of Oct4
66
.  
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Epigenetic control of Oct4 has also been proven important for its transcriptional 
regulation. By comparing the DNA methylation status of the upstream region of Oct4 
between ES cells and trophoblast stem cells it was revealed that this region was 
hypomethylated in ES cells, while hypermethylated in trophoblast stem cells
67
. This 
together with that ES cell regulatory regions were hyperacetylated, and that 
hyperacetylation and demethylation of NIH 3T3 cells were enough to activate Oct4, 
demonstrate the power of the epigenetic control on Oct4 expression
67
.  
Sox2 and Nanog 
Sox2 contains at least two regulatory regions, named SRR1 and SRR2
68
. The latter 
has been shown to contain a somewhat unique Octamer/Sox regulatory element, with 
both of the sequences being different in some aspects to their corresponding 
consensus sequences
68
. Both Sox2:Oct4 and Sox2:Oct6 can bind to the SRR2 and 
activate the transcription of Sox2
68
. Oct6 has increased expression in embryonic 
ectoderm compared to ES cells, consequently, the Sox2:Oct6 complex is probably 
involved in the regulation of Sox2 in embryonic ectoderm
68
. 
Nanog also contains an Octamer/Sox cis-regulatory element, proven to be essential 
for its transcription, and Oct4 together in a complex with either Sox2
69-70
 or a yet 
unidentified factor
70
 were shown to regulate this transcription in ES cells. Other still 
unknown regulatory factors are also important for Nanog transcription given that 
Oct4 knockout embryos still express Nanog
49
. 
 
Cell cycle  
ES cells have a very unique cell cycle in comparison with differentiated somatic 
cells, with their unusual cell cycle structure and rapid cell proliferation as 
characteristics. The cell cycle consists of four distinct phases: G1, S (DNA 
replication), G2 and M (chromosome segregation). Generation time for murine ES 
cells are extremely short and the cells go through the cell cycle in approximately 8-
12 hours, primarily owing to a truncated G1 phase giving an ES cell cycle mostly 
consisting of S phase cells
71-72
. Murine ES cells also share many features with 
transformed cells: they do not undergo senescence or quiescence, are not subject to 
contact inhibition or anchorage dependence and can multiply in the absence of 
serum. Human ES cells share most of these properties, but they are less studied than 
their murine counterpart. Human ES cells also have a truncated G1 phase, but a 
somewhat longer cell cycle in comparison with murine ES cells, of approximately 
15-16 hours
73
.  
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Cdk-cyclin complexes 
Somatic cells show a strict activation pattern of Cdk-cyclin complexes to obtain 
proper transitions from one cell cycle phase to the next in the correct order
74
. Each of 
the gap phases (G1 and G2, respectively) also contain checkpoints to enable 
detection of DNA damage or nucleotide depletion (Figure 4A). These properties are 
not shared with murine ES cells. The latter show constitutively high Cdk2-cyclin E 
and Cdk2-cyclin A levels, undetectable levels of Cdk4-cyclin D, modest levels of 
cyclin D1 and D3 in complex with Cdk6 and only Cdk1-cyclin B has an activity that 
is changing during the cell cycle phases
71,75-76
 (Figure 4B). Inhibition of Cdk2 
activity in ES cells is rate-limiting for cell cycle progression, but surprisingly not 
affecting the cell cycle structure
71
.  
Human ES cells differ from murine ES cells in level and distribution of different 
Cdk-cyclin complexes during the cell cycle with most Cdk-cyclin complexes 
showing a cell cycle dependent expression
77
. Cyclin D2 levels, with a peak during 
G1/S transition, are rate-limiting for their cell cycle progression
78
. Cdk2 has 
important roles both in cell cycle regulation as well as maintaining the pluripotent 
phenotype, given that Cdk2 depletion results in cells arrested in G1 as well as 
decreased  levels of  several pluripotency markers
77
.  
Retinoblastoma (Rb) is often considered as a negative regulator of the cell cycle 
progression and a positive regulator of cellular differentiation. In somatic cells, Rb 
functions as an obstacle in G1, and Rb needs to be phosphorylated by Cdk2-cyclin E 
before the cells are allowed to enter S phase
79
. In contrast, most Rb in ES cells are 
hyperphosphorylated during the whole cell cycle and total Rb content is also 
decreasing from exit of mitosis to entry of S phase
72
. This effectively omits early G1 
phase by bypassing the restriction point that separates early G1 from late G1 and 
partly explains the truncated G1 phase of ES cells. 
 
Figure 4. Comparison of Cdk-cyclin patterns between somatic cells and murine ES cells. 
(A) Somatic cells use Cdk-cyclin complexes to get through the cell cycle by a strict activation pattern.  
(B) Murine ES cells on the other hand have continuously high levels of certain Cdk-cyclin complexes and  
      only Cdk1-cyclin B has a cell cycle changing pattern.  
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Nuclear reprogramming 
There are several possible procedures to achieve reprogramming of an adult somatic 
nucleus to either an embryonic like state or directly towards a different cell type. The 
most studied procedures are: somatic cell nuclear transfer, fusion of somatic cells 
with ES cells and induction of pluripotent stem cells with viral-mediated transduction 
of different sets of transcription factors. Below, each of these methods will be 
discussed in detail. 
 
Somatic cell nuclear transfer 
The most efficient nuclear reprogramming method is the somatic cell nuclear transfer 
(SCNT). The first successful cloning experiments in Xenopus laevis
1
 as well as the 
creation of Dolly the sheep
2
 were obtained using SCNT. This method also offers a 
potential route to produce patient specific ES cells. This would be accomplished by 
inserting the nucleus of an already differentiated adult cell, like a patient’s skin cell, 
into a donated enucleated egg. The egg cytoplasm contains the necessary components 
that are needed to reprogram the genetic material of the skin cell back towards a 
pluripotent state and can then be stimulated to divide to blastocyst stage. This is 
followed by isolation and culturing of ICM resulting in ES cells that are genetically 
identical with the original skin cell (Figure 5). If the blastocyst instead is implanted 
into a uterus, known as reproductive cloning, it can result in a cloned embryo as in 
the case of Dolly the sheep.  
 
Figure 5. Illustration of SCNT procedure to 
create personalized ES cells. A nucleus from 
a somatic adult cell is placed into an 
enucleated egg, where it becomes 
reprogrammed back towards a pluripotent 
state and then can start dividing, forming a 
blastocyst, where ICM can be removed for 
ES cell culture. 
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Even though this seems really promising and quite easily done, SCNT has certain 
limitations that require improvement before this method can be used in clinical 
applications. Depending on how efficiency of SCNT is calculated, it differs from less 
than 1% up to 80%
80
. A large part of this difference was proven to be the 
differentiation and epigenetic state of the donor nuclei
81
. A major drawback is also 
that the SCNT method has not yet been successful with human donor cells to produce 
ES cell lines. However, a Korean group reported that they had succeeded in 
generating cloned human ES cells
82-83
, but it was later shown that these reports were 
fraudulent with fabricated data. Human cloned blastocyst stage embryos produced 
via SCNT experiments have been obtained
84
, but non-human primates are still the 
highest mammal where SCNT has been successful in generating ES cells
85
.  
Besides the lack of success in human SCNT, the largest drawback of this method is 
the need of donated oocytes and the ethical aspects that arise from this. Is it ethically 
correct to do therapeutic cloning, when the terminated blastocyst could develop into a 
cloned embryo if implanted into a uterus? Reproductive cloning of humans is banned 
in most countries and how can anyone be certain that SCNT will not be used to 
create human clones? Truly difficult and important questions to consider. Hopefully 
will the benefits, if successful with human cells, overcome the drawbacks. Reports 
showing the therapeutic potentials of SCNT in mouse models, for example that 
genetic immune defects could be corrected
86
, imply what may be done in the future 
of regenerative medicine using SCNT. 
 
Fusion of somatic cells with ES cells 
Cell-cell fusion occurs spontaneously in both developmental and pathological 
processes in vivo and can either be homo- or heterotypic. This method can also be 
used in vitro to study reprogramming mechanisms, when cell fusion is either 
chemically induced with polyethylene glycol or occurring spontaneously. Both 
human and murine ES cells have been shown to possess the capacity of 
reprogramming somatic cells after cell fusion
87-88
. By fusing an adult somatic cell 
with an ES cell, one can get hybrid cells that share many characteristics with ES 
cells. This route could be a good way of creating genetically tailored patient specific 
ES cell lines to use for biochemical or genetic studies as well as the study and 
treatment of human diseases. Before it can be used in regenerative medicine one 
major obstacle needs to be solved, which is that the hybrid cells get a tetraploid DNA 
content. A pathway of removing single whole chromosomes has recently been 
developed
89
, but not yet shown to eliminate the obstacle of tetraploidy with hybrid 
cells. Controversial reports argue about whether the ES cell factors needed for 
reprogramming of somatic cells exist in the nucleus
90
 or in the cytoplasm
91
, if the 
latter is true it would remove the problem with tetraploidy. Poor efficiency is, as with 
all reprogramming methods, another drawback that needs improvement. The number 
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of formed hybrid colonies were shown to increase by fusing neural stem cells with 
Nanog overexpressing ES cells, but overexpression of Nanog alone in neural stem 
cells was not enough to promote reprogramming
58
.    
 
Induced pluripotent stem cells 
The latest breakthrough in reprogramming somatic cells came a few years ago when 
Takahashi and Yamanaka did the first successful experiments with reprogramming 
mouse embryonic and adult fibroblasts using viral-mediated transduction of only four 
transcription factors: Oct4, Sox2, c-Myc and Klf4
92
. Soon after, successful 
experiments were performed with human fibroblasts and other more terminated 
somatic cells, as well as different sets of transcription factors were shown to work
37-40
 
(Figure 6). These induced pluripotent stem (iPS) cells are similar to ES cells in 
epigenetic states, morphology, expression of pluripotency markers, cell proliferation 
and ability to differentiate to all three embryonic germ layers. Pluripotency markers 
become reactivated at different time-points during iPS cell creation with alkaline 
phosphatase occurring first, followed by SSEA1, and fully reprogrammed cells 
occurring with Oct4 or Nanog expression
93
.  
The major advantages with this method are that no oocytes are needed and that the 
procedure works with human cells. Even though a major breakthrough and step 
toward personalized regenerative medicine, some major issues require to be solved 
before it can be used in clinics. Low efficiency (average 0.001-0.2%) is one of these 
problems. A recent report showed that the differentiation stage influenced the 
reprogramming potential of immature and mature hematopoietic cells
94
. The poor 
efficiency was also shown to partly depend on that reprogramming triggers a stress 
response with characteristics of senescence
95
. Epigenetic silencing of Ink4a/Arf 
locus
96
, or usage of p53 siRNA
97
, both strategies leading to immortalization, were 
also shown to improve the potential to generate iPS cells. The use of oncogenes and 
retroviral transduction to induce reprogramming factors represent additional serious 
barriers that need to be solved before it potentially can be used in regenerative 
medicine. The oncogene c-Myc has been shown to be dispensable for iPS cell 
creation, although resulting in even lower efficiency
98-99
. New approaches to avoid 
retroviral transductions are reported continuously: replacing factors with small 
molecules
100
, using adenoviral vectors
101
, plasmid transfection
102
, recombinant 
proteins
103
 or starting with cells endogenously expressing three of the factors, like 
neural stem cells
104
, are just some examples.  
Not long after the initial successful iPS cell creation, the first report on the potential 
of such cells in personalized treatment of degenerative diseases was published
105
. A 
sickle-cell anemia mouse model was rescued after transplantation with its own 
corrected hematopoietic progenitors obtained from iPS cell creation
105
. 
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Another report showed that iPS cell derived neurons injected into the fetal brain of 
rats with Parkinson’s disease improved their symptoms106. One must bear in mind 
that a lot of safety issues, besides the ones already mentioned above, need to be 
solved before this method can be used in clinics, like elimination of ES cells from the 
differentiated cells to minimize the risk of tumor formation. 
 
Specific proteins of interest 
In this thesis we have come to focus upon four different proteins beside the core 
transcription factors, i.e. translationally controlled tumor protein, nucleophosmin, 
nucleolin and scaffold attachment factor A, and these following sections will 
highlight some parts of what previously are known about these proteins, both 
generally and specifically in ES cells. 
 
Translationally controlled tumor protein 
Translationally controlled tumor protein (Tpt1, also denoted TCTP, Histamine-
releasing factor HRF, Fortilin or P23) shows very low sequence homology with other 
known proteins. However, a relationship to the guanine nucleotide-free chaperone 
Mss4 has been observed
107
. Tpt1 is highly conserved and expressed in all eukaryotes 
and encodes for a hydrophilic protein of 21-23 kDa. It was initially identified due to 
an abundance in ribonucleoprotein particles in mouse tumor cell lines
108
. Tpt1 
contains a highly mobile polypeptide sequence (aa. 39-65), which contains two serine 
residues that are subject to phosphorylations by polo-like kinase 1 (Plk1)
109
.  
Figure 6. Illustration of how creation of iPS cells can 
be done with viral induction of different sets of 
transcription factors, into adult skin fibroblasts, which 
becomes reprogrammed back towards a pluripotent 
state. The created iPS cells can self-renew or 
differentiate into desired cell types, similar to ES 
cells. 
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Tpt1 has been shown to be important for embryonic development. Knockout mice 
deficient in both Tpt1 alleles are embryonic lethal and dependent on deletion of the 
entire gene
110
 or part of the gene
111-112
, death occurs around E3.5 or E6.5-E9.5, 
respectively. The homozygous mutant embryos showed a general growth deficiency 
in combination with a severely disorganized structure, due both to an increase in 
apoptosis and a decrease in cell proliferation
111-112
. Further, proteome analysis of 
murine ES cell lines has revealed that the presence of Tpt1 is a characteristic of 
undifferentiated ES cells
113
, with high Tpt1 expression levels being reported in both 
murine
114
 and human
115
 ES cells, while neural differentiation is accompanied with a 
decrease of Tpt1
116
. Tpt1 has also been found to influence Oct4 expression in 
transplanted somatic cell nuclei
117
. In addition, pretreatment of bovine somatic donor 
cells with phosphorylated Tpt1 gave a beneficial effect in SCNT experiments, 
resulting in an increased efficiency to develop normal cloned calves
118
. 
No primary function of Tpt1 is known, but it has been shown to be calcium and 
microtubule binding, important for cell growth, cell cycle progression, malignant 
transformation, inflammatory processes and anti-apoptotis
119
. Accumulating evidence 
suggests that Tpt1 has an essential role in cell cycle progression. Overexpression of 
Tpt1 results in decreased growth rates together with a delayed cell cycle 
progression
120
, whereas overexpression of a Tpt1 double mutant, in which the two 
Plk1 phosphorylation sites have been substituted for alanines, induced an increase in 
multinucleated cells, rounded cells with condensed ball-like nuclei and apoptotic 
cells
109
. Lower cell proliferation was also observed in prostate
121
 and colon
122
 cancer 
cell lines after knockdown of Tpt1 using RNA-interference. High levels of Tpt1 are 
often found in several cancer tissues or cell lines and human Tpt1 has been 
demonstrated to make cancer cells adopt more malignant phenotypes. It is the one 
gene that exhibits the strongest differential expression between tumor and tumor-
reversed states in human leukemia and breast cancer cells and inhibition of Tpt1 
expression results in suppression of the malignant phenotypes
123
. Further analysis 
strengthened the idea to use Tpt1 as a target for tumor reversion
124
 and is now 
considered a good candidate to use in cancer treatments. 
A possible reason for the tumorigenic properties, besides its role in cell proliferation, 
is that Tpt1 has been proven to be anti-apoptotic
125
. Tpt1 shows a physical and 
functional interaction with the anti-apoptotic proteins Mcl-1
126
 and Bcl-xL
127
. A 
possible mechanism for the anti-apoptotic role of Tpt1 together with its two 
interaction partners have been proposed, where they function through inhibiting the 
apoptotic protein Bax to perform dimerization
112
. 
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Nucleophosmin 
Nucleophosmin (Npm1, also denoted B23, NO38 or numatrin) belongs to the 
nucleophosmin/nucleoplasmin family of proteins (together with Npm2 and Npm3) 
and is a multifunctional nucleolar phosphoprotein. Some of the functions reported for 
Npm1 are: ribosome biogenesis, nucleo-cytoplasmic transportation, centrosome 
duplication, embryonic development, cell proliferation, transcriptional regulation, 
and histone chaperoning
128
. Cell cycle dependent posttranslational modifications, 
together with different interaction partners, are responsible for Npm1’s involvement 
in the different functions mentioned above. Cdk2-cyclin E phosphorylates Npm1 
during G1, which is proven to be required for correct centrosome duplication
129
. 
Npm1 residue S4 becomes phosphorylated by Plk1 during mitosis, and interference 
with this phosphorylation induced multiple mitotic defects, including fragmentation 
of nuclei and incomplete cytokinesis
130
. Further, acetylation of Npm1 by p300 is 
involved in enhanced chromatin transcriptional activation
131
. 
Npm1 has been proven essential for embryonic development given that knockout 
mice deficient in both Npm1 alleles are embryonic lethal and die around E11.5-
E12.5, due to severe anemia
132
. The homozygous embryos had reduced size together 
with an incomplete frontal brain organogenesis with a total absence of the eye
132
. 
Npm1 are expressed at high levels in both murine
114
 and human
115
 ES cells. 
Depletion of Npm1 in ES cells using RNA-interference, resulted in reduced cell 
proliferation, while Oct4 and Nanog levels were unaffected
133
. Regarding cell 
proliferation, several reports in other cell systems have come to the same conclusion, 
namely that Npm1 levels are proportional to the cell growth rate
134-137
. Npm1 is also 
involved in transcriptional regulation, both by activating
131
 and repressing
138
 
transcription. No specific Npm1 binding site has been found, so the most likely 
explanation for its role in transcriptional regulation is that Npm1 functions as a 
histone chaperone that can remodel the local chromatin structure
139
.  
Npm1 is often found overexpressed in different types of tumors, and is therefore 
proposed to serve as a marker for ovarian, gastric, colon and prostatic carcinomas, at 
the same time as it is one of the most frequent targets for genetic alterations in 
hematopoietic tumors
140
 . Contradictory reports exist if Npm1 functions as a tumor 
suppressor or an oncogene. Overexpression of Npm1 results in malignant 
transformation
138,141
, probably due to that Npm1 and the oncogene c-Myc directly 
interact, and Npm1 was proven to function as a key cofactor to c-Myc to induce 
hyperproliferation and transformation of normal cells
141
. Npm1 has also been 
implicated in the control of chromosomal ploidy and DNA repair, as well as to 
function with the tumor suppressor protein p53
140
.   
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Nucleolin 
Nucleolin (Ncl, also denoted C23), one of the most abundant non-ribosomal proteins 
in the nucleoli, belongs to a large family of RNA binding proteins and is a 
multifunctional phosphoprotein. It has been implicated in functions like chromatin 
remodeling, ribosome biogenesis, cell proliferation, DNA replication, nucleogenesis, 
transcriptional regulation and nucleo-cytoplasmic transport
142
. Ncl is a substrate to 
several kinases, which are regulating its functions and localization during the cell 
cycle. CK2 extensively phosphorylates Ncl serine residues during interphase
143
, 
while cdc2 phosphorylates Ncl threonine residues
 
during mitosis
144
.  
Rapidly dividing cells have functionally hyperactive Ncl compared to nondividing 
cells. Consequently, it is not surprising that high levels of Ncl is found in tumors
145
 
and in other rapidly dividing cells, such as ES cells
114-115
. A contributing explanation 
for this is that the stability of Ncl is increased in proliferating cells by inhibiting its 
self-cleaving activity
146
. In ES cells, the nucleolar protein LYAR was shown to 
participate in this inhibition by interacting with Ncl
147
. Accumulated evidence show 
that Ncl plays an important role in cell proliferation. Depleting Ncl using RNA-
interference results in reduced cell growth rate and increased apoptosis in ES cells
147
. 
In other cell systems, Ncl has been proven to be required for correct mitosis, given 
that the absence of Ncl shows an extended cell cycle with misaligned chromosomes 
and deficiency in spindle organization
148
. Absence of Ncl has also been shown to 
result in growth arrest, accumulation in G2, increased apoptosis, nuclear alterations, 
as well as defects in centrosome duplication
149
.  
One additional function of Ncl is to participate in chromatin remodeling, where Ncl 
has been proposed to be involved in both induction of chromatin condensation
150
 as 
well as decondensation
151
 by binding to histone H1. This property might explain why 
Ncl has been found to interact with or be a component of several transcription factor 
complexes, both activating
152
 and repressing
153
 transcription. One of the transcription 
factor complexes is the B cell-specific transcription factor LR1, composed of Ncl and 
hnRNP D
154
. LR1 has been shown to regulate c-Myc transcription in B-cell 
lymphomas
155
, and Ncl has independently been found to be a c-Myc target gene, 
where c-Myc induces Ncl levels
156
.  
 
Scaffold attachment factor A 
Scaffold attachment factor A (SAF-A, also known as heterogeneous nuclear 
ribonucleoprotein-U, hnRNP U) is a nuclear protein belonging to the hnRNP family, 
which constitutes of more than 20 different proteins, preferentially involved in RNA 
processing
157
. Two isoforms exist of human SAF-A, yielded by alternative splicing, 
both binding to single- and double-stranded DNA and RNA as well as to the scaffold 
attached region element MII
158
. SAF-A contains clustered repeats of Arg-Gly-Gly 
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tripeptides, termed the RGG box, which were shown to be the required region for its 
RNA binding activity
159
. During apoptosis SAF-A’s DNA binding domain becomes 
cleaved, resulting in loss of DNA binding activity together with detachment from 
nuclear substructures and possibly also contributing to nuclear breakdown
160
.  
No knockout mice exists with SAF-A, although a hypomorphic mutant results in 
embryonic lethality
161
. Homozygous mutated embryos showed abnormalities at E6.5 
and were resorbed by E10.5
161
. Cell lines isolated from homozygous mutants showed 
that SAF-A levels were 2-5 times lower compared to wild-type cells, suggesting that 
specific amounts of SAF-A is required for normal embryonic development
161
. It has 
been proposed that SAF-A enhances the expression of certain genes by stabilizing 
their mRNA
162
. Other studies suggest that SAF-A is involved in transcriptional 
regulation, like SAF-A binding to the promoter of the ES cell important protein Klf2 
together with hnRNP D, p300 and PCAF
163
. SAF-A and p300 were independently 
found to interact, accompanied with local acetylation of nucleosomes possibly 
poising nontranscribed genes to get ready for transcription
164
.  
A functional association was reported between SAF-A and β-actin in the nuclei of 
HeLa cells, probably involved in the transcription of RNA pol II
165
. In the same study 
they showed that the complex also interacts with the CTD of RNA pol II
165
. PCAF 
was later shown to interact with SAF-A and β-actin both at the RNA pol II promoter 
as well as with the CTD of RNA pol II
166
. The binding of SAF-A to RNA pol II have 
independently been shown to work as an inhibitor of CTD phosphorylation and 
therefore thought to function as a repressor of the elongation process
167
.   
 Helena Johansson  
27 
 
Aspects of methodology 
Confocal microscopy (Paper I-IV) 
Confocal microscopy is an important tool for a wide range of investigations in 
biological and medical sciences, used for imaging thin optical sections in living and 
fixed samples. It offers several advantages over conventional widefield optical 
microscopy, including the ability to choose focal plane where the image is taken, 
elimination or reduction of out-of-focus background fluorescence, as well as the 
capability to collect serial optical sections from thick samples.   
In this thesis we used an inverted Zeiss LSM 510 META confocal microscope 
equipped with a Zeiss image processing system to analyze all of our fluorescently 
stained ES cells. An 63x/1.4 NA oil objective and sequential scanning with narrow 
band-pass filters were used (420-480 nm for DAPI or Hoechst 33342, 505-530 nm 
for Alexa 488 and 560-615 nm for Alexa 555). Sequential scanning of various 
fluorophores reduces possible crossover and bleed-through, which can be a 
significant problem with simultaneous multiple-wavelength excitations.  
 
Colocalization analysis (Paper I-II) 
Colocalization is a quantifying tool used to analyze the degree of association and 
codistribution of stained proteins or structures in a sample, by counting their 
overlapping pixels.  
Confocal micrographs were collected at 0.38 µm intervals to create z-series image 
stacks. Images rendered from the z-series were analyzed for changes/differences in 
colocalization with BioPix iQ 2.0 software. A minimum of five different z-series 
image stacks, containing at least 10 cells each, were taken for each analysis. The 
software calculates Pearson’s correlation coefficient, the number of overlapping 
pixels as well as the total number of pixels in each channel. Pearson’s correlation 
coefficient describes the degree of overlap between the pattern of two labeled 
proteins, with resulting values ranging between -1 and 1. Values between -1 and 0 
indicate some form of inverse relationship between the two channels, while values 
between 0 and 1 indicate a proportional degree of overlap, with 1 showing a 
complete correlation and 0 representing no correlation. Using the obtained pixel 
values we calculated percentage overlap of each protein with the formula: 
                                
There are a lot of different aspects that need to be taken into consideration when 
preparing and analyzing colocalization experiments. Antibodies need to be raised in 
      Overlapping pixels 
                                             = Percentage overlap 
  Total number of pixels 
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Figure 7. Illustration of the 
different steps in situ 
proximity ligation assay 
(PLA):  
1: Primary antibodies  
2: Secondary antibodies  
with attached PLA probes  
3: Hybridization  
4: Ligation  
5: Amplification 
6: Detection 
different species and not be cross-reactive. Fluorochromes should also have well-
separated spectrums. Confocal microscope settings as well as proper control samples 
are needed to ensure that no bleed-through or autofluorescence will give false results. 
 
In situ proximity ligation assay (Paper I-IV) 
In situ proximity ligation assay (PLA) is a recent method to investigate protein-
protein interactions and to visualize their cellular localization
168
.  The methodology 
detects both heavy and light chains of IgG antibodies whereas only light chain of 
IgM antibodies are detected, making IgG more suitable than IgM. The major 
advantages with this method are the ability to visualize where the protein complexes 
are located within the cells, and that even low amounts of protein-protein interactions 
can be detected. 
Prior to in situ PLA, cells are fixed with paraformaldehyde, permeabilized with the 
detergent Triton X-100 and blocked with proper serum solution. In situ PLA 
(Duolink) can be described in six different steps (Figure 7). 1, Incubation with two 
primary antibodies, which must have been raised in different species, specific to the 
proteins of interest. 2, Addition and incubation of secondary antibodies conjugated 
with oligonucleotides (PLA probes). 3, Hybridization step with addition of 
oligonucleotides that hybridize the two PLA probes together if they are in close 
proximity. 4, Ligation step where Ligase is added and closes the circle. 5, 
Amplification step where nucleotides (not shown) and Polymerase is added and starts 
a rolling circle amplification creating a concatameric product with one PLA probe as 
a template. 6, Detection step where small oligonucleotides labeled with Alexa 613 
fluorescence is added and hybridize to the rolling circle amplification product, 
making every detected protein-protein complex appear as a red dot when visualizing 
with confocal microscopy. Hoechst 33342 is added in the last step to counterstain 
DNA. 
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Inhibition assay (Paper I) 
In situ PLA can be used in combination with different cellular treatments against 
specific posttranslational modifications to analyze if the modifications are involved 
in regulating the protein-protein interaction of interest.  
To analyze the involvement of different kinases on newly found protein-protein 
interactions, ES cells were treated with two different Plk1 inhibitors (BI2536 or 
wortmannin) and one Cdk-cyclin inhibitor (purvalanol A) prior to in situ PLA 
analysis. Each experimental setup contained an internal control for individual 
comparison, i.e. one treated and one non-treated sample, to eliminate experimental 
variances from different experiments. 
 
Cell proliferation (Paper I) 
Cell proliferation assays are used to examine the number of cells still being able of 
synthesize new DNA after different treatments. This was examined using Click-iT
™ 
EdU Imaging Kit (Invitrogen), which is a novel alternative to BrdU for measuring 
DNA synthesis. BrdU requires both DNA denaturation and harsh permeabilization 
steps, which may affect the morphology as well as the staining with additional 
antibodies. EdU has the advantage of not requiring DNA denaturation since it uses 
small molecules for detection and consequently not affect the additional antibody 
staining.  
EdU at final concentration of 10 µM was added and incubated in 37°C for two hours, 
to cells transfected with different constructs, to incorporate in newly synthesized 
DNA. EdU incorporation was detected according to manufacturer’s protocol with the 
additional antibody detection step included to visualize GFP positive cells. GFP 
positive cells were manually counted as either proliferating (EdU positive) or none 
proliferating (EdU negative) and compared to empty vector (pEPI-GFP) or GFP 
tagged negative shRNA control. 
 
Transfection (Paper I and III-IV) 
Transfecting cells with either vectors or shRNA is a popular tool to study the effects 
of overexpression or depletion of proteins.  
ES cells are difficult to transfect. However, according to the manufacturer’s standard 
protocol, Lipofectamine LTX (Invitrogen) together with transfecting cells four hours 
post seeding
169
, gave proper transfection results. Twenty four hours post transfection 
selection was started by adding puromycin to wells containing shRNA constructs 
with puromycin selection. 
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Aims 
ES cells hold great potential in regenerative medicine, although many molecular 
mechanisms are still unsolved. The overall aim of this thesis has been to identify 
stem cell factors that are important for ES cells. Main focus has been on finding 
novel protein-protein interactions as well as identifying their functions.  
Specific aims of the project: 
 To understand more about Tpt1 regarding interaction partners as well as 
cellular functions (I, II, IV). 
 
 To understand how the ES cell important protein Oct4 is regulated (III). 
 
 To find novel ES cell specific protein-protein interactions (I-IV). 
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Results and discussion 
Tpt1/Npm1 interaction is involved in cell proliferation of ES cells (Paper I) 
Poor efficiency of reprogramming somatic cells using different methods require more 
basic investigations to identify additional proteins that increase the effectiveness of 
the reprogramming route. Tpt1 could be such a protein since it has been found to 
influence Oct4 expression in SCNT procedures
117
, as well as increasing efficiency of 
successful reprogramming of bovine somatic cells by pretreating donor cell nuclei 
with phosphorylated Tpt1
118
. However, not much is known about Tpt1 in ES cells 
and since ES cells are different compared to somatic cells in several aspects, we 
addressed how Tpt1 behaved in those cells.  
Tpt1 subcellular localization changes during differentiation 
Tpt1 cellular localization in other cell systems has shown contradictory results, with 
a majority reporting about cytoplasmic localization, although nuclear localization has 
also been observed
125-126
. Using western blot and immunofluorescence analysis, we 
found that Tpt1 is detectable in both cytoplasm and nucleus in undifferentiated ES 
cells, however, to some extent, slightly higher in the nucleus. When cell 
differentiation is induced, by either LIF withdrawal or addition of RA, both 
localization and amount of Tpt1 are changing. Total amount of Tpt1 gets decreased, 
particularly in the nucleus, giving a preferential cytoplasmic localization in 
differentiated cells.  Embryonic carcinoma cells showed the same type of Tpt1 
distribution as differentiated cells, with lower total protein levels as well as mostly 
cytoplasmic distribution. Our findings are in agreement with the reports that Tpt1 
levels are decreasing when ES cells differentiate into neuronal lineages
116
, and that 
high Tpt1 levels are a characteristic of undifferentiated ES cells
113
.  
Tpt1 interacts with Npm1 in a cell cycle dependent manner 
To explore Tpt1’s role in ES cells, we screened for novel interaction partners using 
recombinant Tpt1 covalently linked to cyanogen bromide activated sepharose beads, 
which were incubated with ES cell extract. Potential interacting partners were eluted 
with increasing ionic strength, separated by SDS-PAGE and stained with coomassie 
brilliant blue dye. Bands of interest were excised and identified by nano-LC FT-ICR 
mass spectrometry. In the 0.7 M NaCl elute we identified Npm1 as a potential 
interaction partner. 
We found that Tpt1/Npm1 colocalize in ES cells and that the colocalization is 
substantially higher in mitotic cells. This observation was quantified using BioPix iQ 
2.0 software, which gave high values in all calculated parameters indicating good 
colocalization between the two proteins. However, significantly higher colocalization 
in mitotic cells compared to interphase cells were observed. Induced cell 
differentiation by treatment with RA for up to 72 hours resulted in an approximately 
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linear decrease in colocalization. To explore the interaction in further detail in situ 
PLA was used. Three different antibody combinations all gave consistent results; 
Tpt1/Npm1 interacts most prominently during mitosis but also exists in interphase 
cells. Additionally, Npm1 was co-immunoprecipitated using anti-Tpt1, further 
strengthening that endogenous Tpt1 physically interacts with endogenous Npm1 in 
ES cells. 
Tpt1/Npm1 interacts independently of Plk1 phosphorylation 
Since Plk1 previously has been shown to phosphorylate both Tpt1
109
 and Npm1
130
 
during mitosis we wanted to investigate if the Tpt1/Npm1 interaction is regulated by 
Plk1 phosphorylation. To this end we treated ES cells with two different Plk1 
inhibitors: wortmannin
170
 and BI2536
171
. Wortmannin treatment, which arrest cells 
around metaphase, resulted in markedly weaker but also fewer PLA signals, as well 
as a substantial cell size increase. Contradictory, BI2536 treatment, which arrest cells 
in prophase, did not affect PLA signals. These contradictory results could have 
several possible explanations. While BI2536 is a specific Plk1 inhibitor, wortmannin 
also inhibits several other kinases, such as phosphoinositide-3-kinase, ATM, ATR 
and DNA-PKcs
172
. The difference observed might therefore be explained by that it is 
one of the other kinases, inhibited by wortmannin, which is involved in regulating the 
Tpt1/Npm1 interaction. Another possible explanation is that Plk1 is involved in the 
regulation of Tpt1/Npm1 complexes, but that this regulation is occurring in later 
stages of mitosis, explaining the lack of effect from BI2536, since it arrest cells in the 
first stage of mitosis. Attempts of pre-arresting cells at metaphase, by adding 
demecolcine, prior to BI2536 treatment were unsuccessful since mitotic cells are 
attached very loosely to the chamber slides and therefore were lost when the 
demecolcine block was washed away. Overall, our results reveal that the Tpt1/Npm1 
interaction is independent of phosphorylation by Plk1, at least during the early stages 
of mitosis. Given that BI2536 arrest cells early in mitosis, we cannot exclude that 
Plk1 has some regulatory effect in later stages of mitosis, nor that other kinases might 
regulate this complex although further studies are needed to evaluate this. 
Tpt1/Npm1 interaction is involved in ES cell proliferation 
Both Tpt1 and Npm1 have previously been proven to be involved in cell proliferation 
in different cellular systems
109,120,134-137
. To investigate the involvement of Npm1 and 
Tpt1 alone and as a complex on cell proliferation in ES cells, we transfected cells 
with both pEPI-GFP-Tpt1 and pEPI-GFP-Npm1 vectors or shRNA constructs against 
Tpt1 and Npm1 to study effects of increased and decreased protein levels, 
respectively, in combination with EdU proliferation assay. Npm1 overexpression 
resulted in increased cell proliferation (14.7%). Tpt1 overexpression resulted in both 
a decreased cell proliferation (15.9%) as well as a large increase of cells with 
condensed ball-like nuclei (63% of all transfected cells). This is in accordance with 
earlier studies in other cell systems where overexpression of Tpt1 resulted in slow 
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growing cells
120
 or increased number of cells with condensed ball-like nuclei
109
. Dual 
overexpression of Tpt1 and Npm1 stabilized proliferation to normal ES cell rate, 
indicating that Tpt1/Npm1 complexes are involved in promoting cell proliferation for 
ES cells.  
Depletion of Tpt1 or Npm1 alone resulted in significant decrease in cell proliferation 
compared with negative control vector at both 48 and 72 hours post transfection 
(Figure 8). Tpt1 depleted cells showed 9% and 13.7% less cell proliferation while 
Npm1 depleted cells resulted in 10.2% and 18.5% less cell proliferation compared 
with negative shRNA control at 48 and 72 hours post transfection, respectively. Dual 
Tpt1 and Npm1 depletion gave a yet larger decrease with 21.1% and 35.8% less cell 
proliferation compared with the negative shRNA control. At 72 hours post 
transfection, the observed reduction in proliferative cells are greater than the 
calculated multiplicative effect of the combination of Tpt1 and Npm1 depletion. The 
calculated value is 29.7% reduction and our observed value is 35.8%.   
ES cells show many similarities with carcinogenic cells, and both Tpt1 and Npm1 are 
often found at elevated levels in tumors and speculatively possess carcinogenic 
properties
119,140
. Our finding that Tpt1/Npm1 is involved in ES cell proliferation 
might also be true for tumor cells, where the complex very well could have the same 
or similar functions, making this complex a potential therapeutic target to hinder cell 
proliferation of carcinogenic cells. An interesting hypothesis that needs further 
investigations. 
Cell cycle dependent interactions involving Ncl-P, Tpt1 and Oct4 (Paper II) 
Successful reprogramming of somatic cells require proper embryonic genome 
activation. The nucleolus has been proposed to serve as a marker for this process 
since it coincides with the timing of nucleogenesis in rhesus monkey
173
. Ncl, one of 
the most abundant non-ribosomal proteins in the nucleoli, is a multifunctional 
Figure 8. Depleting Tpt1 and 
Npm1 both alone or in 
combination reduces the 
number of EdU incorporated 
cells significantly. 
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protein
142
. To fill the knowledge gaps about Ncl in ES cells, we started by searching 
for novel Ncl interaction partners. 
Ncl interacts with Tpt1 in a cell cycle dependent manner depending on 
phosphorylations on Ncl 
In our previous search for Tpt1 interacting partners in ES cells (paper I), we obtained 
several additional proteins in the 1.0 M NaCl elute, which were identified by nano-
LC FT-ICR mass spectrometry. One of the identified proteins was Ncl, and the 
Ncl/Tpt1 interaction was further investigated. Ncl was co-immunoprecipitated with 
anti-Tpt1 in nuclear, but not cytoplasmic ES cell extracts nor with IgG control. Using 
colocalization analysis, we found that Ncl only colocalize with Tpt1 when Ncl is 
phosphorylated (Ncl-P), and that the colocalization is most prominent during mitosis. 
This observation was quantified using BioPix iQ 2.0. To investigate if differentiation 
affected the Ncl-P/Tpt1 complexes, ES cells were induced to differentiate by addition 
of RA. Colocalization was shown to significantly decrease after 72 hours of RA 
induced differentiation. Also in situ PLA verified that Ncl-P and Tpt1 interact and 
that the interaction is most prominent during mitosis. Three different antibody 
combinations were tested with the PLA method, but only two antibody combinations 
resulted in complexes. A possible explanation of the lack of detected complexes in 
the third combination can be that the epitope recognized by the antibody is the part 
where the interaction occurs and therefore is blocked for antibody detection. 
Given that we found that Ncl only interacts with Tpt1 when phosphorylated, the 
interaction predominantly occurs during mitosis and decreases when ES cells were 
induced to differentiate, all pointing toward a possible function for Ncl-P/Tpt1 in cell 
proliferation. Both Tpt1 and Ncl have individually been shown to be involved in cell 
proliferation in other cell systems. Concerning these aspects, further analysis using 
shRNA and overexpression in combination with EdU proliferation assay could be 
used to investigate these theories. 
Since Tpt1 now has been proven to interact with both Npm1 (paper I) and Ncl-P 
(paper II) in a cell cycle dependent manner with a peak during mitosis and it 
previously has been shown that Npm1 and Ncl interact
174
, one could speculate if all 
three proteins occur in a single complex. However, since Ncl/Npm1 has been shown 
not to interact during prometaphase and metaphase
174
 and we observed the individual 
interactions of Ncl-P/Tpt1 and Tpt1/Npm1 during these phases, it suggests that they 
are not part of a single complex. 
Ncl-P interacts with Oct4 during interphase in both murine and human ES cells 
The staining pattern of Ncl-P in interphase cells resembles the staining pattern of 
Oct4, and since both proteins have been shown to be involved in transcriptional 
regulation, we investigated if they interact in ES cells. We found that Ncl-P/Oct4 
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colocalize during interphase in ES cells and this observation was quantified using 
BioPix iQ 2.0. In situ PLA also verified the interaction between Ncl-P and Oct4 
during interphase. Although similar as with Ncl-P/Tpt1, three antibody combinations 
were tested but only two combinations detected complexes, and the anti-Ncl not 
resulting in complexes was different compared to the Ncl-P/Tpt1 interaction. This 
further strengthens our theory that the reason of lacking complexes is due to that the 
epitope recognized by the antibody is the part where the interaction occurs and 
therefore is blocked for antibody detection. We used in situ PLA to investigate if the 
interaction is specific to murine ES cells or also exist in human ES cells. The 
experiments showed that the interaction also exists in human ES cells at the same 
time as human ES cells that spontaneously had started to differentiate showed a large 
increase in Ncl-P/Oct4 complexes. No such observation was found with murine ES 
cells. 
When comparing literature one find interesting similarities (underlined) between the 
Oct4 binding motif (AGTCAAAT) and the binding site for the transcription factor 
complex LR1 (CCTCCTGGTCAAGGCTGAA), which Ncl is a component of
175
. It 
is therefore tempting to speculate that Ncl-P and Oct4 are components of a 
transcription factor complex, which mostly is active during the initiation of 
differentiation, due to the increased amount of complexes observed in those cells. 
Unfortunately none of our anti-Ncl can immunoprecipitate Ncl. Otherwise ChIP 
experiments at Oct4 binding regions would be interesting to perform, to see if our 
speculation is correct or not. 
SAF-A binds to the Oct4 proximal promoter (Paper III) 
Oct4 is essential for ES cell maintenance as well as nuclear reprogramming in both 
SCNT and iPS cell creation. Specific regulatory mechanisms for Oct4 are still partly 
unsolved and a better understanding of Oct4 regulation could improve the 
reprogramming efficiencies to create patient specific ES cells.  
SAF-A binds the Oct4 proximal promoter and shows involvement in Oct4 expression 
In an attempt to find novel proteins involved in the regulatory mechanisms of Oct4 
expression, we screened for factors only binding to CR1 in the Oct4 proximal 
promoter, when ES cells were sustained in an undifferentiated state. Using DNase 
footprinting, DNA affinity chromatography followed by identification with nano-LC 
FT-ICR mass spectrometry and ChIP followed by qPCR, we showed that SAF-A 
binds preferentially to the unmethylated 1A-like region in the Oct4 proximal 
promoter in undifferentiated ES cells. Initiation of differentiation by LIF withdrawal 
resulted in substantially less SAF-A bound to the Oct4 proximal promoter. SAF-A 
was also found to bind to the Nanog promoter in a similar manner, mostly occurring 
in undifferentiated ES cells. We tested if SAF-A is involved in general transcriptional 
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regulation, using shRNA against SAF-A in combination with incorporation of 5-
ethynyl uridine, and found that there was little correlation between SAF-A 
expression and global transcription in ES cells. 
To explore the involvement of SAF-A on Oct4 expression, RNA-interference was 
performed in combination with both immunofluorescence and qPCR. Depletion of 
SAF-A was accompanied by an approximate 50% decrease in Oct4 levels (both 
mRNA and protein), together with a 50% increase in the mesodermal marker 
Brachyury, 48 and 96 hours post transfection, respectively, suggesting a loss of 
pluripotency and directed differentiation towards mesodermal lineages. We also 
showed that ectopic expression of human SAF-A could rescue the knockdown 
phenotype. To further explore the involvement of SAF-A in Oct4 expression, eGFP 
tagged SAF-A constructs were prepared and transfected into ES cells. 
Immunofluorescence analysis was used to visualize effects on Oct4 in respect to 
elevated SAF-A levels. Increased levels of a truncated version of SAF-A, lacking the 
C-terminal aa. 553-806, gave decreased levels of Oct4. Less transfected cells were 
also observed with the truncated SAF-A construct implying lethality of this particular 
construct. Increased levels of full length SAF-A resulted in some cells showing 
increased levels of Oct4, although high endogenous expression of SAF-A and Oct4 
makes it difficult to interpret.  
SAF-A interacts with RNA pol II, Oct4, Sox2 and STAT3 
Previous reports have suggested that SAF-A interacts with RNA pol II in other cell 
systems
165,167
. To investigate if that is the case also in ES cells we performed in situ 
PLA and co-immunoprecipitation. We found that SAF-A and RNA pol II interact in 
ES cells and that the interaction is independent of mRNA and CTD phosphorylations. 
All the above indicate a possibility of SAF-A being involved in the transcriptional 
initiation of Oct4. Oct4 is known to self-regulate by binding to the distal enhancer as 
a heterodimer with Sox2
66
. To see if SAF-A also exists in close proximity to Oct4 
and Sox2, in situ PLA was again employed, and showed that SAF-A binds close to 
both Oct4 and Sox2 in ES cells. Induced differentiation by LIF withdrawal resulted 
in less complexes for both Oct4/SAF-A and Sox2/SAF-A.  
To our great surprise differentiation induced by LIF withdrawal does not decrease 
SAF-A mRNA and protein levels. In contrary, SAF-A initially increases and then 
returns to original levels at day three. Thus, Oct4 downregulation cannot be credited 
simply to a decrease in SAF-A levels. Since murine ES cells are dependent on added 
LIF working through the JAK/STAT pathway with STAT3, we explored the possible 
interaction between SAF-A and STAT3 with in situ PLA, which were shown to 
interact, providing an important link in a chain of interactions ranging from extrinsic 
signaling of LIF, to intrinsic response in the nucleus, resulting in Oct4 expression.  
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If SAF-A’s sole task in the chain of transcriptional regulation was to control Oct4 
expression, it would only generate two complexes in each in situ PLA experiment 
together with RNA pol II, provided that Oct4 is a subject to biallelic expression in ES 
cells. Since that is not the case, it is tempting to speculate that SAF-A controls a 
larger set of genes in ES cells. We have found that SAF-A also binds to the Nanog 
promoter and one report shows the binding of SAF-A to the promoter of the 
pluripotency gene Klf2
163
. Further investigations about this is required to explore 
SAF-A’s true role in ES cell maintenance.  
Additional Npm1 and Tpt1 interactions in ES cells (Paper IV) 
To further explore the role of Npm1 and Tpt1 in ES cells, we wanted to investigate if 
proteins important for ES cell maintenance and iPS cell creation have any connection 
to Tpt1 and Npm1. Npm1 has previously been found to interact with c-Myc and that 
the interaction is involved in cell proliferation
141
.  
Npm1 interacts with all three core transcription factors 
In order to investigate if Npm1 interacts with any of the proteins characterized as 
important for maintenance of ES cells and iPS cell creation, we used in situ PLA to 
screen for novel protein-protein interactions. We found Npm1 to individually interact 
with all three core transcription factors: Oct4, Sox2 and Nanog. All three interactions 
occur in the nucleoplasm of interphase cells, so Npm1 should be phosphorylated, 
since it is outside of the nucleolus. Using an antibody recognizing phosphorylated 
Npm1 (Npm1-P), we showed that Oct4 and Npm1-P create protein complexes also 
during mitosis, although in a lesser extent compared to the amount of complexes 
found during interphase. Npm1 was co-immunoprecipitated together with anti-Sox2 
and induced differentiation for 24 hours, by either LIF withdrawal or addition of 
either RA or DMSO, resulting in that the number and intensity of Npm1/Sox2 
complexes were decreased with LIF withdrawal and DMSO addition, while sustained 
or even slightly increased with RA addition. This implies that Npm1/Sox2 has a 
function not only in ES cells but also in ectodermal cells, at least during the initial 
stages of differentiation. Given that Npm1 shows individual interactions with all 
three core transcription factors, it might have something to do with transcriptional 
regulation. Previously it has been shown that Npm1 functions as a histone chaperone 
that remodels local chromatin structures
139
. The most logical explanation for these 
three interactions would be that Npm1 remodels the chromatin structure so that the 
different transcription factors can bind and activate the specific genes. Several other 
possible functions include cell cycle regulation and directed differentiation, but 
additional analyzes are needed before any conclusions can be drawn.  
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Tpt1 interacts with Oct4 but Tpt1 depletion does not affect Oct4 expression 
Previously it has been shown that Tpt1 influences Oct4 expression in transplanted 
somatic cell nuclei
117
. Using in situ PLA, Tpt1 and Oct4 were found to interact in ES 
cells independently of cell cycle stage. No interaction was observed between Tpt1 
and Sox2 or with Nanog. To examine if depletion of Tpt1 affected Oct4 expression 
we used shRNA constructs to deplete Tpt1 from ES cells in combination with qPCR. 
Forty eight hours post transfection we had a decrease of Tpt1 to approximately 50%, 
but found no obvious effect on Oct4. If any effect, it was a slight increase in Oct4, 
contradictory to the results of Koziol
117
. We did not have any possibility to select for 
cells transfected with Tpt1 shRNA and only obtained a 50% decrease in the Tpt1 
levels. This could explain why we got contradictory results, given the high 
expression of Tpt1 in ES cells
114-115
, so that the 50% Tpt1 remaining could be enough 
to keep the Oct4 expression at a normal level. 
Tpt1 and Npm1 depletion induce different differentiation markers 
To explore if Tpt1 and Npm1 are important for ES cell maintenance, shRNA against 
Tpt1 and Npm1 were used in combination with qPCR to analyze the effect of their 
depletion on the levels of Oct4, Sox2, Nestin (ectoderm), Brachyury (mesoderm) and 
GATA4 (endoderm). We found that decreasing Tpt1 with approximately 50% gave an 
increase in Sox2 (approximately 100%) and in Nestin (approximately 50%), implying 
that the downregulation of Tpt1 is connected to differentiation towards ectodermal 
lineages. This is in accordance with a previous finding, where Tpt1 levels were 
shown to decrease during neural cell differentiation
116
. When depleting Npm1, we 
observed a minor increase in Oct4 and Sox2 levels (approximately 10%), together 
with a larger increase in the mesodermal marker Brachyury (approximately 40%). 
This support our earlier finding that Npm1 is needed for differentiation toward 
ectodermal lineages, since depletion of Npm1 did not affect the ectodermal marker 
Nestin.  
Even though we have found several new characteristics for both Tpt1 and Npm1 in 
ES cells, there are certainly still more fascinating aspects to consider to get the full 
picture about these interesting proteins. Would the ectopic expression of this pair of 
proteins enhance the efficiency of iPS cell creation? One recent report added Tpt1 
together with Oct4, c-Myc, Klf4 and Sox2, but found no increased efficiency in iPS 
cell creation
97
. Although the combination of Tpt1 and Npm1 have not been tested, 
and given the results we present here about their involvement in cell proliferation and 
interaction partners, it would be really interesting to explore. Also the aspect if they 
are a potential therapeutic target for effective elimination of cancer cells would be 
intriguing to study further. 
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Npm1 and SAF-A show a large interaction in ES cells 
Not included in any of the papers in this thesis is the finding that Npm1 and SAF-A 
show a large interaction in the nucleoplasm of interphase cells (Figure 9A). The 
Npm1/SAF-A interaction also exists during cell-division, with a peak during the last 
phases of mitosis, i.e. anaphase and telophase (Figure 9B, indicated by arrows). The 
complex pattern of Npm1/SAF-A resembles a previously known interaction between 
Npm1 and histone H3
131
 (Figure 9C). We tested a possible function in both cell 
proliferation and transcription with shRNA depletion, but did not see any obvious 
involvement. A possible decrease in cell proliferation with less EdU incorporated is 
observed as well as some correlation with transcription, but this needs to be further 
investigated in detail before any conclusions can be drawn. Another interesting 
result, except the found interaction, is that dual depletion of SAF-A and Npm1 results 
in a high increase (approximately 300%) of the mesodermal marker Brachyury 96 
hours post transfection. This also needs to be further analyzed.   
 
  
Figure 9. In situ PLA experiments showing the interaction between Npm1/SAF-A 
(A-B) and Npm1/H3 (C) in ES cells (red dots). Arrows in (B) indicate a cell being 
in the last phases of cell-division. DNA was counterstained with Hoechst 33342  
(blue) and scale bar represents 10 µm. 
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Concluding remarks 
 In this thesis, we have in total found twelve novel protein-protein 
interactions in ES cells, summarized in Figure 10. 
 
 Tpt1 was found to interact with Npm1 in a cell cycle dependent manner, 
with a significant peak during mitosis and decrease during differentiation. 
Tpt1/Npm1 interaction occurs independently of phosphorylations by Plk1 
and was found to collaborate in ES cell proliferation. Dual depletion gave a 
larger decrease in cell proliferation than their combined individual decrease. 
 
 Ncl was found to interact individually with Tpt1 and Oct4 in a cell cycle 
dependent manner, where Ncl needs to be phosphorylated for both 
interactions to occur. Ncl-P/Tpt1 interaction occurs mostly during mitosis 
and decreases with differentiation, proposing that it may have a function in 
cell proliferation. Ncl-P/Oct4 interaction occurs during interphase both in 
human and murine ES cells, and might be part of a transcription factor 
complex. 
 
 SAF-A was found to bind preferentially to the unmethylated Oct4 proximal 
promoter, and alteration of SAF-A protein levels affected the mRNA and 
protein levels of Oct4. SAF-A was found to interact with RNA pol II, 
STAT3, Oct4 and Sox2. 
 
 Npm1 forms complexes with all three core transcription factors: Oct4, Sox2 
and Nanog. Npm1/Sox2 interaction is sustained or slightly increased when 
ES cells are induced to differentiate along the ectodermal pathway, while 
decreasing in the other two differentiation pathways. Tpt1 forms complexes 
with Oct4, but neither with Sox2 nor Nanog. Depletion of Tpt1 and Npm1 
increases specific differentiation markers, indicating their importance for ES 
cell maintenance. 
 
  
Figure 10. Novel ES cell protein-
protein interactions presented in 
this thesis. Blue circles represent 
the four proteins we came to focus 
upon. Purple circles represent the 
three core transcription factors. 
Pink circles represent additional 
proteins. 
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doktorandtid nämligen min älskade Björn. Utan dig hade jag inte klarat av det här, 
du har fått ner mig på jorden och fått mig att inse vad som betyder något här i livet 
och att nästan allt i alla fall löser sig till slut. Du har fått mig att fortsätta kämpa och 
ge allt den sista tiden. Utan ditt stöd hade inte det här varit möjligt för mig att 
genomföra. Har gjort många underbara resor med dig genom åren och hoppas på 
många fler! Älskar dig mest av allt!!!  
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